SGLT2 inhibitors and how we use them

Date Published: 
Wednesday, February 24, 2021

In this podcast, Dr Rick Cutfield discusses the management of type two diabetes mellitus following the introduction of new funded medication in NZ.

He covers the importance of lifestyle, medication, and support at every step, and also the pharmacological management including the new stepwise approach to management.

Indications and precautions of the new classes of subsidised medications: Sodium glucose co-transporter 2 (SGLT-2) inhibitors, and briefly Glucagon like peptide-1 receptor (GLP-1) agonists are also covered.



  • 00:37 lifestyle interventions
  • 03:18 updated guidelines
  • 12:51 UTIs
  • 13:48 monitoring
  • 14:50 HbA1c maximum drop
  • 15:30 reducing hospitalisations
  • 20:22 diabetes in NZ going forward
  • 21:57 health equity
  • 22:20 take-home messages

Take-home messages

  • Stick with lifestyle changes.
  • Continue to use metformin safely. Think about using dual agents.
  • Don’t forget about insulin, but we will be using it far less.
  • Think of diabetes as a condition where heart disease and kidney disease is to be absolutely prevented.
  • Think about cancer screening.





Dr Rick Cutfield

Dr Rick Cutfield is the Clinical Director of the Endocrinology & Diabetes Division at Waitemata DHB. He is active in teaching, clinical research and all aspects of diabetes, endocrinology and general medicine.



Supported by an independent medical education grant from:

Recognition of Learning Activities

Complete and submit the learning reflection form for CPD/MOPS points provided by The Royal New Zealand College of General Practitioners below for recognition of learning activities.

Learning Reflection Form

This presentation is intended for qualified health practitioners professional development and should not be relied upon for any other purpose. Any opinions offered are those of the presenter or other speaker and do not necessarily represent the views of Goodfellow Unit.